Activation of the innate immune system and vascular inflammation in patients with type 1 diabetes mellitus

Activation of the innate immune system and vascular inflammation in patients with type 1 diabetes mellitus - Activation innate immune system in type 1 diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44648

Enrollment

Registered

2017-09-05

Start date

2018-01-18

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Atherosclerosis

Diabetes

Inflammation

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Group 1: Type 1 diabetes, HbA1c > 64 mmol/mol; Group 2: Type 1 diabetes, HbA1c

Exclusion criteria

Exclusion criteria: - Inability to provide informed consent - Smoking - Specific Medication use: o Use of immunosuppressive drugs o Use of statins 30 kg/m2 - Pregnancy - Claustrophobia - Severe hypoglycaemia

Design outcomes

Primary

Measure	Time frame
Vascular wall inflammation in the aorta, left and right carotid artery and left and right iliac and femoral arteries, as quantified by FDG-PET scanning.	—

Secondary

Measure	Time frame
FDG uptake in spleen and bone marrow. Ex vivo determination of the inflammatory/atherogenic phenotype, cellular metabolism of circulating monocytes and epigenetic signature of monocytes.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)